Advertisement

Bioluminescent Ligand–Receptor Binding Assays for Protein or Peptide Hormones

  • Ya-Li Liu
  • Zhan-Yun GuoEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1461)

Abstract

Bioluminescence has been widely used in biomedical research due to its high sensitivity, low background, and broad linear range. In recent studies, we applied bioluminescence to ligand–receptor binding assays for some protein or peptide hormones based on a newly developed small monomeric Nanoluciferase (NanoLuc) reporter that has the so far brightest bioluminescence. The conventional ligand–receptor binding assays rely on radioligands that have drawbacks, such as radioactive hazards and short shelf lives. In contrast, the novel bioluminescent binding assays use the NanoLuc-based protein or peptide tracers that are safe, stable, and ultrasensitive. Thus, the novel bioluminescent ligand–receptor binding assay would be applied to more and more protein or peptide hormones for ligand–receptor interaction studies in future. In the present article, we provided detailed protocols for setting up the novel bioluminescent ligand–receptor binding assays using two representative protein hormones as examples.

Key words

Bioluminescence Binding Ligand Peptide Protein Receptor Tracer 

Notes

Acknowledgments

We thank Promega Corporation for providing the plasmids encoding NanoLuc. This work was supported by the National Natural Science Foundation of China (31470767, 31270824) and the Fundamental Research Funds for the Central Universities (2000219098).

References

  1. 1.
    Frank LA, Krasitskaya VV (2014) Application of enzyme bioluminescence for medical diagnostics. Adv Biochem Eng Biotechnol 144:175–197PubMedGoogle Scholar
  2. 2.
    Badr CE (2014) Bioluminescence imaging: basics and practical limitations. Methods Mol Biol 1098:1–18CrossRefPubMedGoogle Scholar
  3. 3.
    Scott D, Dikici E, Ensor M, Daunert S (2011) Bioluminescence and its impact on bioanalysis. Annu Rev Anal Chem (Palo Alto, Calif) 4:297–319CrossRefGoogle Scholar
  4. 4.
    Hall MP, Unch J, Binkowski BF, Valley MP, Butler BL, Wood MG, Otto P, Zimmerman K, Vidugiris G, Machleidt T, Robers MB, Benink HA, Eggers CT, Slater MR, Meisenheimer PL, Klaubert DH, Fan F, Encell LP, Wood KV (2012) Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem Biol 7:1848–1857CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bylund DB, Toews ML (2011) Radioligand binding methods for membrane preparations and intact cells. Methods Mol Biol 746:135–164CrossRefPubMedGoogle Scholar
  6. 6.
    Hulme EC, Trevethick MA (2010) Ligand binding assays at equilibrium: validation and interpretation. Br J Pharmacol 161:1219–1237CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Sykes DA, Dowling MR, Charlton SJ (2010) Measuring receptor target coverage: a radioligand competition binding protocol for assessing the association and dissociation rates of unlabeled compounds. Curr Protoc Pharmacol, Chapter 9: Unit 9.14
  8. 8.
    McKinney M, Raddatz R (2006) Practical aspects of radioligand binding. Curr Protoc Pharmacol, Chapter 1: Unit 1.3
  9. 9.
    de Jong LA, Uges DR, Franke JP, Bischoff R (2005) Receptor-ligand binding assays: technologies and applications. J Chromatogr B Analyt Technol Biomed Life Sci 829:1–25CrossRefPubMedGoogle Scholar
  10. 10.
    Thibault G, Schiffrin E (2001) Radioligand binding assay. Methods Mol Med 51:305–314PubMedGoogle Scholar
  11. 11.
    Handl HL, Gillies RJ (2005) Lanthanide-based luminescent assays for ligand-receptor interactions. Life Sci 77:361–371CrossRefPubMedGoogle Scholar
  12. 12.
    Selvin PR (2002) Principles and biophysical applications of lanthanide-based probes. Annu Rev Biophys Biomol Struct 31:275–302CrossRefPubMedGoogle Scholar
  13. 13.
    Zhang WJ, Jiang Q, Wang XY, Song G, Shao XX, Guo ZY (2013) A convenient method for europium-labeling of a recombinant chimeric relaxin family peptide R3/I5 for receptor-binding assays. J Pept Sci 19:350–354CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang WJ, Gao XJ, Liu YL, Shao XX, Guo ZY (2012) Design, recombinant preparation and europium-labeling of a fully active easily-labeled INSL3 analogue for receptor-binding assays. Process Biochem 47:1856–1860CrossRefGoogle Scholar
  15. 15.
    Zhang WJ, Luo X, Song G, Wang XY, Shao XX, Guo ZY (2012) Design, recombinant expression and convenient A-chain N-terminal europium-labelling of a fully active human relaxin-3 analogue. FEBS J 279:1505–1512CrossRefPubMedGoogle Scholar
  16. 16.
    Zhang WJ, Luo X, Liu YL, Shao XX, Wade JD, Bathgate RA, Guo ZY (2012) Site-specific DOTA/europium-labeling of recombinant human relaxin-3 for receptor-ligand interaction studies. Amino Acids 43:983–992CrossRefPubMedGoogle Scholar
  17. 17.
    Zhang L, Song G, Xu T, Wu QP, Shao XX, Liu YL, Xu ZG, Guo ZY (2013) A novel ultrasensitive bioluminescent receptor-binding assay of INSL3 through chemical conjugation with Nanoluciferase. Biochimie 95:2454–2459Google Scholar
  18. 18.
    He SX, Song G, Shi JP, Guo YQ, Guo ZY (2014) Nanoluciferase as a novel quantitative protein fusion tag: application for overexpression and bioluminescent receptor-binding assays of human leukemia inhibitory factor. Biochimie 106:140–148CrossRefPubMedGoogle Scholar
  19. 19.
    Liu Y, Shao XX, Zhang L, Song G, Liu YL, Xu ZG, Guo ZY (2015) Novel bioluminescent receptor-binding assays for peptide hormones: using ghrelin as a model. Amino Acids 47:2237–2243CrossRefPubMedGoogle Scholar
  20. 20.
    Maguire JJ, Kuc RE, Davenport AP (2012) Radioligand binding assays and their analysis. Methods Mol Biol 897:31–77CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Research Center for Translational Medicine at East Hospital, College of Life Sciences and TechnologyTongji UniversityShanghaiChina

Personalised recommendations